The Uromigos

Episode 371: TROPICS-04 Results from ESMO Asia 07.12.2024 33:43 ↓

Jonathan Rosenberg joins Brian and Tom to discuss this important phase 3 trial and efficacy and toxicity signals.

Episode 370: Artificial Intelligence in Medical Oncology 02.12.2024 44:46 ↓

Jacob Kather joins Brian and Tom to discuss emerging AI applications in Oncology

Episode 369: Paper of the Month with Bishoy Faltas 25.11.2024 45:51 ↓

Bishoy joins us to discuss his work on extrachromosomal DNA in bladder cancer from his latest Nature publication

Episode 368: Radiomics in RCC: Live from IKCS 19.11.2024 37:00 ↓

Andrew Smith from St. Jude's joins us to discuss the emerging field of radiomics and shares his hopes and skepticism

Episode 367: Abiraterone vs AR inhibitors (Fanta vs Coke) in Prostate Cancer 11.11.2024 56:48 ↓

Chuck Ryan from MSKCC joins to talk about various aspects of AR inhibition in prostate cancer and relative benefits and risks.

Episode 366: ARPIs in Prostate Cancer - Are They Different? 04.11.2024 31:51 ↓

Chris Sweeney and Rob Jones join Brian and Tom to discuss the relative merits of different ARPIs in prostate cancer.

Episode 365: A Review of the Advanced Prostate Cancer Consensus Conference (APCCC) 28.10.2024 47:59 ↓

Episode 365: Silke Gillessen and Betrand Tombal join the show to discuss the APCCC meeting and recent publication.

Episode 361: The Role of Monotherapy AR Inhibition in Prostate Cancer 22.10.2024 25:43 ↓

Betrand Tombal joins Brian and Tom to discuss the historic and current data for AR inhibition with monotherapy with AR blockers.

Episode 360: The SUNRISE Program in Bladder Cancer 15.10.2024 46:19 ↓

Christopher Cutie from J&J joins the show to discuss the SUNRISE bladder program with the gemcitabine-eluting pretzel across several NMIBC and MIBC states.

Episode 359: #UromigosLive24 - IO after IO in RCC 09.10.2024 40:41 ↓

The RCC panel at Uromigos Live 2024 discusses and debates this topic.

Episode 358: Noticias del Dia 1 de Uromigos Live 2024 en Nashville 30.09.2024 21:59 ↓

En este podcast cubrimos los temas de cáncer urotelial discutidos por los Uromigos. El impacto del estudio NIAGARA en utiliar quimio más inmunoterapia en neadyuvancia de Ca urotelial músculo invasor, el uso de pembrolizumab adyuvante después de los datos del estudio AMBASSADOR y la búsqueda de biomarcadores.

Episode 357: #UromigosLive24 - Peri-operative Therapy in Bladder Cancer 30.09.2024 1:03:10 ↓

Tom leads a panel of Shilpa Gupta, Andrea Apolo, Kala Sridhar and Petros Grivas to discuss and debate this timely topic.

Episode 356: #UromigosLive24 - Front-line Therapy in Papillary and Non-clear Cell RCC 28.09.2024 26:22 ↓

Brian moderates the panel that discusses and debates TKI, vs Ipi/Nivo vs IO/TKI

Episode 355: #UromigosLive24 - Radioligands in prostate cancer 28.09.2024 54:23 ↓

The Uromigos Live 2024 panel discusses recent radioligand data including PEACE-3

Episode 354: #UromigosLive24 - T cell directed therapy in prostate cancer 28.09.2024 44:00 ↓

Brian hosts a panel at Uromigos Live 2024 in Nashville with Michael Morris, Tanya Dorff and Karen Autio

Episode 353: #UromigosLive24 ADC session 28.09.2024 53:28 ↓

Tom moderates a live panel of Kala Sridhar, Shilpa Gupta, Andrea Apolo and Petros Grivas on the emerging ADC data in bladder cancer

Episode 352: ESMO 2024 - RCC and Bladder review 23.09.2024 26:25 ↓

Tom and Brian finish discussing ESMO 2024 highlights. Even without a guest Tom still interrupts a lot.

Episode 351: ESMO 2024 review part 1: prostate cancer 21.09.2024 18:48 ↓

Silke joins us to discuss ESMO 2024 highlights, then the birds start singing....

Episode 350: ESMO 2024 - NIAGARA 16.09.2024 23:51 ↓

Fresh of the Presidential session address, Tom discusses his data with Petros commenting.

Episode 348: ESMO 2024 - UpFrontPSMA 15.09.2024 33:52 ↓

Arun Azad describes this randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel vs. docetaxel in mHSPC

Episode 347: ESMO 2024 - DV + Pembro in Urothelial Cancer 15.09.2024 17:59 ↓

Matt Galsky describes his ESMO 2024 abstract of disitimab vedotiin + pembrlizumab in bladder cancer

Episode 346: ESMO 2024 - PEACE-3: Enza/Radium-223 vs Enza in mCRPC 14.09.2024 25:47 ↓

Silke Gillessen joins us to discuss her Presidential session from ESMO 2024

Episode 345: ESMO 2024 - SUNNIFORECAST: Ipi/Nivo vs SOC in Non-clear Cell RCC 14.09.2024 31:10 ↓

Lothar Bergmann describes this investigator-initiated trial of Ipi/Nivo vs SOC in Non-clear Cell RCC

Episode 344: ESMO 2024 - NKT2152, a HIF inhibitor in RCC 14.09.2024 22:32 ↓

Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC

Episode 343: ESMO 2024 - TiNivo-2 Trial 14.09.2024 31:23 ↓

Katy Beckermann discusses the TiNivo-2 study presented at ESMO 2024.